Fig. 6From: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialPharmacokinetics, mean plasma concentration–time curves on treatment Days 1 (A) and 27 (B)Back to article page